NCT02845752View on ClinicalTrials.gov

The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

March 1, 2017

Primary Completion Date

August 6, 2018

Study Completion Date

August 6, 2018

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Stiolto Respimat

Oral inhalation spray

DRUG

Placebo Respimat

Oral inhalation spray

Trial Locations (1)

90502

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

Boehringer Ingelheim

INDUSTRY

lead

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

NCT02845752 - The Effect of STIOLTO™ RESPIMAT® on Fatigue in Chronic Obstructive Pulmonary Disease | Biotech Hunter | Biotech Hunter